Victor F. A. Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victor F. A. Almeida has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Eliana F. R. Duraes
Department of Plastic Surgery, Cleveland Clinic Foundation, Cleveland, USA
4 shared publications - Glaudir Donato
Center of Medical Sciences, Federal University of Paraíba, João Pessoa, Brazil
4 shared publications - Manoela Dantas
Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases Institute, Cleveland Clinic Foundation, Cleveland, Ohio
4 shared publications - Avneep Aggarwal
Division of Surgical Critical Care, Cleveland Clinic, Cleveland, Ohio
2 shared publications Ammar Lakda
Department of Anesthesiology Cleveland Clinic Foundation Cleveland Ohio USA
1 shared publication- Andressa Alves de Carvalho
Universidade Federal da Paraíba
1 shared publication
Latest Publications
- 4 August 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (8) , 2160-2161
Toward Bedside-Ready Artificial Intelligence in Resuscitation: Low-Resolution, High-Value Signals
Was not provided for this article.
- 4 August 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (8) , 2160-2161
Toward Bedside-Ready Artificial Intelligence in Resuscitation: Low-Resolution, High-Value Signals
Was not provided for this article.
- 16 July 2026
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 145 (3) , 797-798
Maintaining Rigor in Language Model Studies: Comment
Was not provided for this article.
- 16 July 2026
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 145 (3) , 797-798
Maintaining Rigor in Language Model Studies: Comment
Was not provided for this article.
- 7 July 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (7) , 1841-1842
Beyond a Snapshot: Tracking Family Prognostic Expectations in the ICU
- 7 July 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (7) , 1841-1842
Beyond a Snapshot: Tracking Family Prognostic Expectations in the ICU
- Open Access
- 3 June 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 119, 343-361
Antidepressants and postoperative complications in breast reduction surgery: A retrospective association study
- 3 June 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 119, 343-361
Open AccessAntidepressants and postoperative complications in breast reduction surgery: A retrospective association study
- 27 April 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 143 (1) , e8-e10
Federated Learning in Anesthesiology: A Privacy-Preserving Approach to Collaborative Predictive Modeling
- 27 April 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 143 (1) , e8-e10
Federated Learning in Anesthesiology: A Privacy-Preserving Approach to Collaborative Predictive Modeling
- 29 December 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (3) , 1071-1072
Ketorolac in Breast Reduction: Balancing Analgesia and Bleeding Risk
The perioperative use of ketorolac in breast reduction surgery requires careful consideration of both its analgesic benefits and potential bleeding risks. In response to recent correspondence, we highlight that our meta-analysis stratified hematomas by severity, recognizing that even conservatively managed cases may influence patient satisfaction in aesthetic surgery. The current evidence base remains limited by heterogeneity in dosing protocols, timing of administration, and surgical techniques, underscoring the need for randomized controlled trials and patient-level data analyses. Although ketorolac may confer opioid-sparing effects, the clinical significance of this reduction has yet to be clearly established. The potential impact on bleeding risk should be carefully evaluated, particularly in patients with additional predisposing factors. Clinical judgment and individualized assessment remain central to optimizing perioperative analgesia and safety in aesthetic breast surgery. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 29 December 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (3) , 1071-1072
Ketorolac in Breast Reduction: Balancing Analgesia and Bleeding Risk
The perioperative use of ketorolac in breast reduction surgery requires careful consideration of both its analgesic benefits and potential bleeding risks. In response to recent correspondence, we highlight that our meta-analysis stratified hematomas by severity, recognizing that even conservatively managed cases may influence patient satisfaction in aesthetic surgery. The current evidence base remains limited by heterogeneity in dosing protocols, timing of administration, and surgical techniques, underscoring the need for randomized controlled trials and patient-level data analyses. Although ketorolac may confer opioid-sparing effects, the clinical significance of this reduction has yet to be clearly established. The potential impact on bleeding risk should be carefully evaluated, particularly in patients with additional predisposing factors. Clinical judgment and individualized assessment remain central to optimizing perioperative analgesia and safety in aesthetic breast surgery. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- Open Access
- 3 October 2025
- Published by Wiley in Microsurgery
- Vol. 45 (7) , e70126
Liposomal Bupivacaine in Transversus Abdominis Plane Block for Postoperative Pain Control After Autologous Breast Reconstruction: A Systematic Review and Meta‐Analysis
Background: Autologous breast reconstruction using abdominally based flaps is common post‐mastectomy, but donor‐site pain often leads to prolonged opioid use. The transversus abdominis plane ( TAP ) block is a common regional anesthesia technique, with bupivacaine as the standard anesthetic. Liposomal bupivacaine ( LB ), a prolonged‐release formulation, aims to extend pain relief and reduce opioid consumption, though its efficacy remains debated. Objective: This systematic review and meta‐analysis compared LB versus plain bupivacaine ( PB ) in TAP blocks for autologous breast reconstruction, focusing on opioid consumption, pain scores, and hospital stay. Methods: A systematic search identified randomized controlled trials and observational studies comparing LB (with or without PB ) to PB in TAP blocks. Data were pooled using a random‐effects model ( I 2 ≥ 25%) or fixed‐effects model ( I 2 < 25%). Results: Six studies (429 patients) met inclusion criteria. LB was associated with significant reduction in opioid consumption on postoperative days ( POD ) 1 ( MD = −4.99 mg; 95% CI : [−8.42; −1.56], p < 0.01, I 2 = 0%) and POD 2 ( MD = −3.35 mg; 95% CI : [−5.74; −0.96], p < 0.01, I 2 = 0%). Pain scores were significantly lower on POD 2 and POD 3. No difference in hospital stay was found ( MD = −0.17; 95% CI : [−0.52; 0.18], p = 0.34, I 2 = 83.1%). Conclusion: LB reduced opioid consumption during the first 48 h postoperatively and modestly improved pain control on POD 2 and POD 3, but did not shorten hospital stay. Further large‐scale RCTs are needed to validate its benefits.
- 3 October 2025
- Published by Wiley in Microsurgery
- Vol. 45 (7) , e70126
Open AccessLiposomal Bupivacaine in Transversus Abdominis Plane Block for Postoperative Pain Control After Autologous Breast Reconstruction: A Systematic Review and Meta‐Analysis
Background: Autologous breast reconstruction using abdominally based flaps is common post‐mastectomy, but donor‐site pain often leads to prolonged opioid use. The transversus abdominis plane ( TAP ) block is a common regional anesthesia technique, with bupivacaine as the standard anesthetic. Liposomal bupivacaine ( LB ), a prolonged‐release formulation, aims to extend pain relief and reduce opioid consumption, though its efficacy remains debated. Objective: This systematic review and meta‐analysis compared LB versus plain bupivacaine ( PB ) in TAP blocks for autologous breast reconstruction, focusing on opioid consumption, pain scores, and hospital stay. Methods: A systematic search identified randomized controlled trials and observational studies comparing LB (with or without PB ) to PB in TAP blocks. Data were pooled using a random‐effects model ( I 2 ≥ 25%) or fixed‐effects model ( I 2 < 25%). Results: Six studies (429 patients) met inclusion criteria. LB was associated with significant reduction in opioid consumption on postoperative days ( POD ) 1 ( MD = −4.99 mg; 95% CI : [−8.42; −1.56], p < 0.01, I 2 = 0%) and POD 2 ( MD = −3.35 mg; 95% CI : [−5.74; −0.96], p < 0.01, I 2 = 0%). Pain scores were significantly lower on POD 2 and POD 3. No difference in hospital stay was found ( MD = −0.17; 95% CI : [−0.52; 0.18], p = 0.34, I 2 = 83.1%). Conclusion: LB reduced opioid consumption during the first 48 h postoperatively and modestly improved pain control on POD 2 and POD 3, but did not shorten hospital stay. Further large‐scale RCTs are needed to validate its benefits.
- Open Access
- 19 September 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (3) , 1057-1066
Perioperative Ketorolac and Hematoma Following Breast Reduction: A Systematic Review and Meta-analysis
Background: Ketorolac, a nonsteroidal anti-inflammatory drug, is a promising opioid-sparing option for postoperative pain control. However, its impact on platelet function raises concerns about bleeding risk. Reduction mammaplasty carries a known risk of hematoma, and this study aimed to assess whether perioperative ketorolac increases this risk. Methods: We searched Cochrane Central, Embase, PubMed, and Web of Science databases for studies involving breast reduction patients who did or did not receive perioperative ketorolac. The primary outcome was hematoma formation, with secondary outcomes distinguishing between cases requiring surgery and those managed conservatively. A random-effects model calculated pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was assessed using the I 2 statistic. Results: Seven studies involving 3,418 patients were included—1991 in the ketorolac group and 1427 in the control group. The hematoma incidence was 6.13% in the ketorolac group versus 6.73% in controls. Meta-analysis revealed a significantly increased risk of hematoma in ketorolac users (OR 2.63, 95% CI 1.58–4.37, p < 0.001, I 2 = 37.5%), particularly in cases managed conservatively (OR 2.72, 95% CI 1.37–5.38, p = 0.004, I 2 = 26.3%). Sensitivity analysis reinforced these findings, also demonstrating an association between ketorolac and hematomas requiring reoperation. Conclusion: Perioperative ketorolac is associated with an increased risk of hematoma following breast reduction surgery. While it provides effective opioid-sparing analgesia, its use should be carefully considered, especially in patients with higher bleeding risks. Further randomized trials are needed to refine safety recommendations. Level of Evidence II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- 19 September 2025
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (3) , 1057-1066
Open AccessPerioperative Ketorolac and Hematoma Following Breast Reduction: A Systematic Review and Meta-analysis
Background: Ketorolac, a nonsteroidal anti-inflammatory drug, is a promising opioid-sparing option for postoperative pain control. However, its impact on platelet function raises concerns about bleeding risk. Reduction mammaplasty carries a known risk of hematoma, and this study aimed to assess whether perioperative ketorolac increases this risk. Methods: We searched Cochrane Central, Embase, PubMed, and Web of Science databases for studies involving breast reduction patients who did or did not receive perioperative ketorolac. The primary outcome was hematoma formation, with secondary outcomes distinguishing between cases requiring surgery and those managed conservatively. A random-effects model calculated pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was assessed using the I 2 statistic. Results: Seven studies involving 3,418 patients were included—1991 in the ketorolac group and 1427 in the control group. The hematoma incidence was 6.13% in the ketorolac group versus 6.73% in controls. Meta-analysis revealed a significantly increased risk of hematoma in ketorolac users (OR 2.63, 95% CI 1.58–4.37, p < 0.001, I 2 = 37.5%), particularly in cases managed conservatively (OR 2.72, 95% CI 1.37–5.38, p = 0.004, I 2 = 26.3%). Sensitivity analysis reinforced these findings, also demonstrating an association between ketorolac and hematomas requiring reoperation. Conclusion: Perioperative ketorolac is associated with an increased risk of hematoma following breast reduction surgery. While it provides effective opioid-sparing analgesia, its use should be carefully considered, especially in patients with higher bleeding risks. Further randomized trials are needed to refine safety recommendations. Level of Evidence II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- Open Access
- 16 July 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 108, 90-92
Explainable artificial intelligence: enhancing decision-making in plastic surgery
- 16 July 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 108, 90-92
Open AccessExplainable artificial intelligence: enhancing decision-making in plastic surgery